Corpus ID: 1566579

Inhaled insulin--does it become reality?

@article{Siekmeier2008InhaledII,
  title={Inhaled insulin--does it become reality?},
  author={R. Siekmeier and G. Scheuch},
  journal={Journal of physiology and pharmacology : an official journal of the Polish Physiological Society},
  year={2008},
  volume={59 Suppl 6},
  pages={
          81-113
        }
}
  • R. Siekmeier, G. Scheuch
  • Published 2008
  • Biology, Medicine
  • Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
After more than 80 years of history the American and European Drug Agencies (FDA and EMEA) approved the first pulmonary delivered version of insulin (Exubera) from Pfizer/Nektar early 2006. However, in October 2007, Pfizer announced it would be taking Exubera off the market, citing that the drug had failed to gain market acceptance. Since 1924 various attempts have been made to get away from injectable insulin. Three alternative delivery methods where always discussed: Delivery to the upper… Expand
Back to the future: inhaled drug products.
  • A. Hickey
  • Medicine
  • Journal of pharmaceutical sciences
  • 2013
TLDR
Inhaled therapeutic aerosols continue to be an important treatment for asthma and pulmonary diseases and recent product development activities and approvals suggest that attitudes may be changing in favor of systemic delivery following inhaled aerosol administration. Expand
Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera.
  • M. Al-Tabakha
  • Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2015
TLDR
The results from this systematic review indicate the effectiveness of insulin inhalation products, particularly for patients initiating insulin therapy, as well as investigating the reasons why Exubera was unsuccessful. Expand
CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARIES Back to the Future: Inhaled Drug Products
TLDR
The new inhaledDrug technologies seem to be driving reconsideration of therapeutic categories for indications that were of interest at the inception of modern inhaled drug therapy in the past century. Expand
TECHNOSPHERE INSULIN INHALER – A REVIEW
Inhaled Insulin is a recent therapeutic advance for the treatment of Diabetes. It offers a convenient, as well as accepted, alternative to injected Insulin. Subcutaneous administration of InsulinExpand
Technosphere® Insulin
Given the important role of insulin in the treatment of diabetes mellitus and in light of common barriers to insulin use, new strategies for insulin delivery by routes other than intravenous andExpand
Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption.
TLDR
Novel molecular or formulation approaches, for example, Technosphere, Fc-/scFv-fusion protein, PEGylation, polymeric or lipid-based micro/nanoparticles and liposomes, offer opportunities to improve lung absorption and therapeutic duration of some biotherapeutics. Expand
The Role of Inhaled Insulin in the Management of Type 2 Diabetes
Type 2 diabetes continues to place a major burden on the health care system of the United States and worldwide. Type 2 diabetes involves two major defects: decreased insulin production from theExpand
Novel non-invasive methods of insulin delivery
TLDR
This review article covers all the most relevant non-invasive insulin delivery methods under development, respective technology and clinical data available according to their status of development, with special focus on the systems with late clinical trial evidences, their achievements and pitfalls. Expand
Farmacocinética de la insulina inhalable: ADME (absorción, distribución, metabolismo y excreción)
Diabetes mellitus is a metabolic disease. For an optimal control and in some cases it is necessary to provide exogenous insulin. To understand the pharmacokinetics of insulin are just models thatExpand
Inhaled Technosphere Insulin: A Novel Delivery System and Formulation for the Treatment of Types 1 and 2 Diabetes Mellitus
TLDR
The pharmacology, pharmacokinetics, drug interactions, clinical safety and efficacy, patient satisfaction, dosage and administration, warnings, precautions, contraindications, adverse effects, and place in therapy of inhaled Technosphere insulin are reviewed in this article. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 136 REFERENCES
The ascent of pulmonary drug delivery.
  • I. Gonda
  • Medicine
  • Journal of pharmaceutical sciences
  • 2000
TLDR
The origins of inhalation therapy can be traced back to the early civilizations but this route of administration was relatively uncommon until recently, and the beginning of the new millennium is likely to witness development of many valuable therapeutic products delivered by inhalation. Expand
Insulin Disposition in the Lung Following Oral Inhalation in Humans
TLDR
The modelling analysis enabled unification of the literature information associated with the kinetics and mechanisms of insulin disposition in the lung following inhalation in humans and enabled derivation of increased values for both ka,L and kmm,L as a possible cause of faster absorption for deep inspiratory manoeuvres and increased absorption in smokers. Expand
Pulmonary delivery of insulin
TLDR
Pharmacokinetic and pharmacodynamic data show that Exubera and other inhaled insulins have a time-action profile that is well suited for mealtime insulin administration and could, therefore, represent a new opportunity for improved glycemic control and health outcomes in patients with diabetes. Expand
Exubera inhaled insulin: a review
  • A. Barnett
  • Medicine
  • International journal of clinical practice
  • 2004
TLDR
Inhaled insulin has been developed to provide more physiological prandial insulin replacement than regular human insulin in patients with diabetes, with the advantage of non‐invasive delivery. Expand
Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery.
TLDR
It appear that after several decades of research, for the first time a feasible alternative route for insulin administration is within reach. Expand
Inhaled insulin: extending the horizons of inhalation therapy.
TLDR
Although there are some limitations to the use of inhaled insulin, the potential to improve adherence and thereby achieve target glycohemoglobin levels (< or = 6.5-7.0%) in poorly controlled diabetic patients outweigh its disadvantages. Expand
Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
TLDR
It is concluded that inhalation of TI leads to a rapid onset of metabolic action resembling the effect observed with i.v. administration of regular HI, and may become a suitable and attractive alternative for prandial insulin delivery, especially for patients with type 2 diabetes mellitus. Expand
Aerosols for systemic treatment
TLDR
Aerosols for systemic drug treatment seems to be a gained alternative to the “syringe” because of its accuracy and the reproducibility, but several problems prohibited its spreading. Expand
Inhaling medicines: delivering drugs to the body through the lungs
TLDR
Advances in lung physiology and formulation composition that influence the systemic delivery of inhaled therapeutics are reviewed. Expand
Pulmonary delivery of insulin by liposomal carriers.
TLDR
Experimental results showed that insulin could be efficiently encapsulated into liposomes by preformed vesicles and detergent dialyzing method, and it was found that the liposomal carriers were effectively and homogeneously distributed in the lung aveolar. Expand
...
1
2
3
4
5
...